• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

TeraRecon previews treatment planning software

Article

Japanese postprocessing firm TeraRecon demonstrated work-in-progress treatment planning software at the ASTRO meeting Nov. 4 to 8. The software, which runs on TeraRecon’s Aquarius workstation, supports treatment planning, dose calculation, and dose

Japanese postprocessing firm TeraRecon demonstrated work-in-progress treatment planning software at the ASTRO meeting Nov. 4 to 8. The software, which runs on TeraRecon’s Aquarius workstation, supports treatment planning, dose calculation, and dose optimization. It features real-time 3-D volume rendering, using the company’s VolumePro technology, as well as such advanced features as interactive image fusion, auto contouring, beam and block entry, dose calculation, and segmented image reconstruction with isodose display. The system can also digitally reconstruct radiographs and generate dose-volume histograms for 3-D structures. An intravascular brachytherapy module provides extended radial and anisotropic dose functions.

Recent Videos
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Teleradiology and Breast Imaging: Keys to Facilitating Personalized Service, Efficiency and Equity
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 3
Related Content
© 2025 MJH Life Sciences

All rights reserved.